Literature DB >> 21530708

Perioperative pharmacology: a focus on vancomycin.

Rodney W Hicks1, Johnanna Hernandez.   

Abstract

Given the increase in various drug-resistant organisms and in patients who are allergic to penicillin, perioperative nurses are likely to encounter patients who are receiving IV vancomycin, a tricyclic glycopeptide antibiotic. In general, vancomycin is not considered a first-line agent because of its possible adverse effects (e.g., hypotension, phlebitis, nephrotoxicity, ototoxicity); therefore, it is reserved for treating serious or severe infections caused by organisms that are unresponsive to other antimicrobial agents. Vancomycin is administered intravenously over a minimum of 60 minutes to avoid infusion-related reactions. Some considerations for nurses administering vancomycin include ensuring a patent IV line, planning for administration of the preoperative dose as much as two hours before the initial incision is made, and including information about the dose and timing of preoperative vancomycin administration in the surgical time out.
Copyright © 2011 AORN, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21530708     DOI: 10.1016/j.aorn.2010.09.031

Source DB:  PubMed          Journal:  AORN J        ISSN: 0001-2092            Impact factor:   0.676


  3 in total

1.  Evaluation of Vancomycin Dosing in Patients With Cirrhosis: Beginning De-Liver-ations about a New Nomogram.

Authors:  Randolph E Regal; Steven P Ren; Gregory Paige; Cesar Alaniz
Journal:  Hosp Pharm       Date:  2018-04-26

2.  Assessment of vancomycin utilization among Lebanese hospitals.

Authors:  Diana N Malaeb; Iqbal M Fahs; Pascale Salameh; Souheil Hallit; Manal Saad; Jassem Bourji; Rabih Hallit
Journal:  Saudi Med J       Date:  2019-02       Impact factor: 1.484

3.  Circulatory collapse during wound closure in spine surgery with an unknown cause: a possible adverse effect of topical application of vancomycin?

Authors:  Xiaoqing Zhang; Wenwen Zhai; Min Li; Xiangyang Guo
Journal:  BMC Anesthesiol       Date:  2021-01-06       Impact factor: 2.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.